Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALEC NASDAQ:CGEM NASDAQ:EVO NASDAQ:PURR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$2.21+4.2%$2.30$1.09▼$3.40$235.37M0.64548,503 shs929,675 shsCGEMCullinan Therapeutics$13.98-2.4%$14.20$5.68▼$16.74$880.69M-0.09964,269 shs705,572 shsEVOEvotec$2.99+5.3%$2.78$2.31▼$4.80$1.01B1.96102,926 shs24,629 shsPURRHyperliquid Strategies$8.48+4.4%$6.02$3.01▼$8.79$1.09B1.449.17 million shs24.09 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector+4.25%-3.91%-10.16%+11.06%+76.80%CGEMCullinan Therapeutics-2.44%-13.44%-1.69%+2.42%+77.64%EVOEvotec+5.28%+9.93%-7.43%-15.30%-25.44%PURRHyperliquid Strategies+4.43%+18.77%+50.35%+97.67%+847,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$2.21+4.2%$2.30$1.09▼$3.40$235.37M0.64548,503 shs929,675 shsCGEMCullinan Therapeutics$13.98-2.4%$14.20$5.68▼$16.74$880.69M-0.09964,269 shs705,572 shsEVOEvotec$2.99+5.3%$2.78$2.31▼$4.80$1.01B1.96102,926 shs24,629 shsPURRHyperliquid Strategies$8.48+4.4%$6.02$3.01▼$8.79$1.09B1.449.17 million shs24.09 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector+4.25%-3.91%-10.16%+11.06%+76.80%CGEMCullinan Therapeutics-2.44%-13.44%-1.69%+2.42%+77.64%EVOEvotec+5.28%+9.93%-7.43%-15.30%-25.44%PURRHyperliquid Strategies+4.43%+18.77%+50.35%+97.67%+847,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.13Hold$3.6364.03% UpsideCGEMCullinan Therapeutics 2.67Moderate Buy$30.75119.96% UpsideEVOEvotec 2.50Moderate Buy$7.00134.11% UpsidePURRHyperliquid Strategies 2.50Moderate Buy$9.259.08% UpsideCurrent Analyst Ratings BreakdownLatest ALEC, CGEM, EVO, and PURR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2026PURRHyperliquid Strategies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (D)5/20/2026PURRHyperliquid Strategies Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.45 ➝ $9.755/19/2026CGEMCullinan Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$38.005/11/2026PURRHyperliquid Strategies Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$6.00 ➝ $8.005/8/2026CGEMCullinan Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$36.00 ➝ $37.005/4/2026ALECAlector Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/4/2026ALECAlector Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingUnderweight$2.005/4/2026CGEMCullinan Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$38.004/28/2026CGEMCullinan Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$38.004/28/2026CGEMCullinan Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.00 ➝ $30.004/24/2026EVOEvotec Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 5/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$21.05M11.66N/AN/A$0.09 per share24.56CGEMCullinan TherapeuticsN/AN/AN/AN/A$5.96 per shareN/AEVOEvotec$891.97M1.19N/AN/A$2.30 per share1.30PURRHyperliquid Strategies$1M1,141.59N/AN/A$5.52 per share1.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$142.93M-$1.19N/AN/AN/A-680.83%-295.17%-40.95%8/6/2026 (Estimated)CGEMCullinan Therapeutics-$219.88M-$3.36N/AN/AN/AN/A-51.45%-47.64%8/6/2026 (Estimated)EVOEvotec-$117.12MN/AN/AN/AN/A-26.20%-24.93%-11.35%N/APURRHyperliquid Strategies-$16.01M-$7.37N/A2.81N/AN/A-56.04%-52.22%N/ALatest ALEC, CGEM, EVO, and PURR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026ALECAlector-$0.2878-$0.21+$0.0778-$0.21$9.67 million$1.05 million5/7/2026Q1 2026CGEMCullinan Therapeutics-$0.8359-$0.75+$0.0859-$0.75$3.67 millionN/A5/7/2026Q3 2026PURRHyperliquid StrategiesN/A$1.01N/A$1.01N/A$2.63 million3/31/2026Q4 2025EVOEvotecN/A$0.05N/A$0.05N/A$297.02 million3/10/2026Q4 2025CGEMCullinan Therapeutics-$0.80-$0.77+$0.03-$0.77$5.56 millionN/A2/25/2026Q4 2025ALECAlector-$0.39-$0.34+$0.05-$0.34$1.78 million$6.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/ACGEMCullinan TherapeuticsN/AN/AN/AN/AN/AEVOEvotecN/AN/AN/AN/AN/APURRHyperliquid StrategiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlector0.805.255.25CGEMCullinan TherapeuticsN/A10.2810.28EVOEvotec0.431.681.60PURRHyperliquid StrategiesN/A18.2318.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%CGEMCullinan Therapeutics86.31%EVOEvotec5.81%PURRHyperliquid Strategies9.45%Insider OwnershipCompanyInsider OwnershipALECAlector8.30%CGEMCullinan Therapeutics8.60%EVOEvotec1.00%PURRHyperliquid Strategies8.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector270111.03 million101.81 millionOptionableCGEMCullinan Therapeutics3061.46 million56.17 millionOptionableEVOEvotec4,553355.33 million351.77 millionNot OptionablePURRHyperliquid StrategiesN/A134.62 million123.21 millionN/AALEC, CGEM, EVO, and PURR HeadlinesRecent News About These CompaniesThe Token Takeover: SEC Triggers Market Quake (PURR)...May 21 at 1:30 PM | marketbeat.comChardan Capital Issues Positive Forecast for Hyperliquid Strategies (NASDAQ:PURR) Stock PriceMay 21 at 3:15 AM | americanbankingnews.comHyperliquid Strategies (NASDAQ:PURR) Hits New 52-Week High Following Analyst UpgradeMay 21 at 1:38 AM | americanbankingnews.com21Shares has a new ETF—and it's in big demand (corrected)May 20 at 7:59 AM | msn.comCathie Woods' 21Shares Has A New ETF—And It's In Big DemandMay 19 at 7:54 PM | msn.comHyperliquid Strategies (PURR) jumps as Hyperliquid’s HYPE token rally boosts its crypto-treasury narrativeMay 19 at 5:31 PM | quiverquant.comQHyperliquid Strategies (NASDAQ:PURR) Price Target Raised to $8.00 at Cantor FitzgeraldMay 12, 2026 | americanbankingnews.comHyperliquid Strategies (NASDAQ:PURR) Price Target Raised to $8.00May 11, 2026 | marketbeat.comWhy Hyperliquid Strategies Keeps Buying HYPE Despite a $165M Net LossMay 9, 2026 | memeburn.comMHyperliquid Strategies Q3 Earnings Call HighlightsMay 8, 2026 | marketbeat.comHyperliquid Strategies Reports $165 Million Loss as HYPE Treasury ExpandsMay 8, 2026 | financefeeds.comFHyperliquid Strategies Reports $152.5 Million Quarterly Profit as HYPE Rally Lifts TreasuryMay 8, 2026 | finance.yahoo.comHyperliquid Strategies Inc. (PURR) Stock: Shares Decline Despite Expanding HYPE Holdings and Rising Staking IncomeMay 8, 2026 | blockonomi.comHyperliquid Strategies Highlights Q3 Results, HYPE Treasury ExpansionMay 7, 2026 | tipranks.comHyperliquid Strategies (NASDAQ:PURR) Issues Earnings ResultsMay 7, 2026 | marketbeat.comHyperliquid Strategies and Unit Labs Announce Validator on HyperliquidMay 7, 2026 | prnewswire.comHyperliquid Strategies Inc Reports Financial Results for the Quarter Ended March 31, 2026May 7, 2026 | prnewswire.comHyperliquid Strategies (NASDAQ:PURR) Hits New 52-Week High - Here's What HappenedMay 6, 2026 | marketbeat.comHyperliquid Strategies Inc Announces Webcast to Discuss Results for the Fiscal Quarter Ended March 31, 2026April 28, 2026 | prnewswire.comHyperliquid Strategies (NASDAQ:PURR) Trading Up 6.9% - Time to Buy?April 27, 2026 | marketbeat.comMaxim Group initiates coverage of Hyperliquid Strategies (PURR) with buy recommendationApril 26, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesIs Backblaze the Next Momentum Monster?By Jeffrey Neal Johnson | May 7, 2026Is This Pre-IPO AI Robotics Company the Next Big Defense Play?By Bridget Bennett | April 30, 2026Uber's Annual Product Showcase Reveals It Is Coming for Airbnb and BookingBy Jessica Mitacek | May 7, 2026From High-Yield to High-Growth: 3 Stocks Boosting DividendsBy Leo Miller | May 18, 2026The Great Cloud Divide: How AI Is Reshuffling the Software DeckBy Jeffrey Neal Johnson | May 20, 2026ALEC, CGEM, EVO, and PURR Company DescriptionsAlector NASDAQ:ALEC$2.21 +0.09 (+4.25%) Closing price 05/21/2026 04:00 PM EasternExtended Trading$2.22 +0.00 (+0.23%) As of 05/21/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Cullinan Therapeutics NASDAQ:CGEM$13.98 -0.35 (-2.44%) Closing price 05/21/2026 04:00 PM EasternExtended Trading$14.18 +0.20 (+1.45%) As of 08:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Evotec NASDAQ:EVO$2.99 +0.15 (+5.28%) Closing price 05/21/2026 04:00 PM EasternExtended Trading$3.00 +0.01 (+0.33%) As of 08:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.Hyperliquid Strategies NASDAQ:PURR$8.48 +0.36 (+4.43%) Closing price 05/21/2026 04:00 PM EasternExtended Trading$8.73 +0.25 (+3.00%) As of 08:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Hyperliquid Strategies Inc is a digital asset treasury company whose primary focus is to maximize shareholder value through accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. Hyperliquid Strategies Inc, formerly known as Sonnet BioTherapeutics Holdings Inc., is based in NEW YORK. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Intuit's Great SaaS Reset: Fired By AI Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish Target Shows Strengths, But Analysts Want to See More Freight Boom: The Hormuz Blockade Payday TJX Companies Fires on All Cylinders With 9% Revenue Growth Analog Devices Provides Much-Needed Pullback: How Low Can It Go? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
